3,000 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,193,000.

A number of other hedge funds also recently modified their holdings of ALNY. OFI Invest Asset Management boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 22 shares in the last quarter. Howard Capital Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,206 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the sale, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. This represents a 3.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares of the company’s stock, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 57,833 shares of company stock worth $19,346,441. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $319.52 on Wednesday. The company has a fifty day moving average price of $325.44 and a 200-day moving average price of $392.98. The company has a market capitalization of $42.38 billion, a P/E ratio of 186.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Wells Fargo & Company dropped their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $473.87.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.